Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1995 Aug;73(2):131–135. doi: 10.1136/adc.73.2.131

A double blind, placebo controlled study of the effects of low dose testosterone undecanoate on the growth of small for age, prepubertal boys.

D C Brown 1, G E Butler 1, C J Kelnar 1, F C Wu 1
PMCID: PMC1511206  PMID: 7574856

Abstract

OBJECTIVE--To assess whether very low doses of testosterone can accelerate growth without an undue advance in bone age in prepubertal boys with constitutional delay of growth. SUBJECTS--23 prepubertal boys aged 11-14 years with height at or below the third centile for chronological age. DESIGN--Randomised, double blind trial comparing oral testosterone undecanoate 20 mg once daily versus placebo for six months. The 18 months' observation period of each subject comprised a six month pretreatment period, followed by a six month treatment (testosterone undecanoate or placebo) period, and a six month period after termination of treatment. OUTCOME MEASURES--At intervals of six months standing and sitting height were measured. Bone age, pubertal stage, weight, and lean body mass were also determined. Growth hormone, luteinising hormone, and follicle stimulating hormone secretion and testosterone concentration were measured before, after, and six months after treatment. RESULTS--Boys taking testosterone undecanoate (n = 11) showed a significantly greater height velocity (mean (SEM) 5.84 (0.53) cm/year) and sitting height velocity (3.54 (0.57) cm/year) during treatment than the placebo treated boys (n = 12, height velocity = 3.38 (0.22) cm/year, sitting height velocity = 1.58 (0.19) cm/year. There were no significant differences between the groups regarding changes in growth hormone, gonadotrophins, testosterone, or dihydrotestosterone concentrations. Bone age was not advanced significantly more rapidly in either group. CONCLUSIONS--There is accelerated gain in height during six months of treatment with low dose testosterone undecanoate, without a significantly greater rise in bone age compared with controls. Testosterone undecanoate is a safe, well tolerated, and effective treatment in the management of constitutional delay of growth.

Full text

PDF
131

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albanese A., Kewley G. D., Long A., Pearl K. N., Robins D. G., Stanhope R. Oral treatment for constitutional delay of growth and puberty in boys: a randomised trial of an anabolic steroid or testosterone undecanoate. Arch Dis Child. 1994 Oct;71(4):315–317. doi: 10.1136/adc.71.4.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Butler G. E., Sellar R. E., Walker R. F., Hendry M., Kelnar C. J., Wu F. C. Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J Clin Endocrinol Metab. 1992 Jul;75(1):37–44. doi: 10.1210/jcem.75.1.1619029. [DOI] [PubMed] [Google Scholar]
  3. Cantrill J. A., Dewis P., Large D. M., Newman M., Anderson D. C. Which testosterone replacement therapy? Clin Endocrinol (Oxf) 1984 Aug;21(2):97–107. doi: 10.1111/j.1365-2265.1984.tb03448.x. [DOI] [PubMed] [Google Scholar]
  4. Clayton P. E., Shalet S. M., Price D. A., Addison G. M. Growth and growth hormone responses to oxandrolone in boys with constitutional delay of growth and puberty (CDGP). Clin Endocrinol (Oxf) 1988 Aug;29(2):123–130. doi: 10.1111/j.1365-2265.1988.tb00254.x. [DOI] [PubMed] [Google Scholar]
  5. Geere G., Jones J., Atherden S. M., Grant D. B. Plasma androgens after a single oral dose of testosterone undecanoate. Arch Dis Child. 1980 Mar;55(3):218–220. doi: 10.1136/adc.55.3.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gordon M., Crouthamel C., Post E. M., Richman R. A. Psychosocial aspects of constitutional short stature: social competence, behavior problems, self-esteem, and family functioning. J Pediatr. 1982 Sep;101(3):477–480. doi: 10.1016/s0022-3476(82)80093-0. [DOI] [PubMed] [Google Scholar]
  7. Gregory J. W., Greene S. A., Thompson J., Scrimgeour C. M., Rennie M. J. Effects of oral testosterone undecanoate on growth, body composition, strength and energy expenditure of adolescent boys. Clin Endocrinol (Oxf) 1992 Sep;37(3):207–213. doi: 10.1111/j.1365-2265.1992.tb02312.x. [DOI] [PubMed] [Google Scholar]
  8. Law C. M. The disability of short stature. Arch Dis Child. 1987 Aug;62(8):855–859. doi: 10.1136/adc.62.8.855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Link K., Blizzard R. M., Evans W. S., Kaiser D. L., Parker M. W., Rogol A. D. The effect of androgens on the pulsatile release and the twenty-four-hour mean concentration of growth hormone in peripubertal males. J Clin Endocrinol Metab. 1986 Jan;62(1):159–164. doi: 10.1210/jcem-62-1-159. [DOI] [PubMed] [Google Scholar]
  10. Marti-Henneberg C., Niirianen A. K., Rappaport R. Oxandrolone treatment of constitutional short stature in boys during adolescence: effect on linear growth, bone age, pubic hair, and testicular development. J Pediatr. 1975 May;86(5):783–788. doi: 10.1016/s0022-3476(75)80373-8. [DOI] [PubMed] [Google Scholar]
  11. PARIZKOVA J. Total body fat and skinfold thickness in children. Metabolism. 1961 Oct;10:794–807. [PubMed] [Google Scholar]
  12. Rosenfeld R. G., Northcraft G. B., Hintz R. L. A prospective, randomized study of testosterone treatment of constitutional delay of growth and development in male adolescents. Pediatrics. 1982 Jun;69(6):681–687. [PubMed] [Google Scholar]
  13. Schürmeyer T., Wickings E. J., Freischem C. W., Nieschlag E. Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol (Copenh) 1983 Mar;102(3):456–462. doi: 10.1530/acta.0.1020456. [DOI] [PubMed] [Google Scholar]
  14. Stanhope R., Brook C. G. Oxandrolone in low dose for constitutional delay of growth and puberty in boys. Arch Dis Child. 1985 Apr;60(4):379–381. doi: 10.1136/adc.60.4.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tanner J. M., Whitehouse R. H. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 1976 Mar;51(3):170–179. doi: 10.1136/adc.51.3.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tanner J. M., Whitehouse R. H., Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I. Arch Dis Child. 1966 Oct;41(219):454–471. doi: 10.1136/adc.41.219.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tanner J. M., Whitehouse R. H., Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. Arch Dis Child. 1966 Dec;41(220):613–635. doi: 10.1136/adc.41.220.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Zachmann M., Prader A., Kind H. P., Häfliger H., Budliger H. Testicular volume during adolescence. Cross-sectional and longitudinal studies. Helv Paediatr Acta. 1974 Apr;29(1):61–72. [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES